|
| | Clopidogrel hydrogen sulfate Chemical Properties |
| Melting point | 184°C | | alpha | D20 +55.10° (c = 1.891 in methanol) | | storage temp. | 2-8°C | | solubility | DMSO: ~26mg/mL | | form | White powder | | color | white | | InChIKey | FDEODCTUSIWGLK-RSAXXLAASA-N | | CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | HazardClass | IRRITANT |
| | Clopidogrel hydrogen sulfate Usage And Synthesis |
| Anti-platelet aggregation drug | Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied.
Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi-Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state.
The above information is edited by the chemicalbook of Kui Ming.
| | Chemical Properties | Colorless to light yellow liqui | | Uses | Used as an antithrombotic | | Uses | rac-Clopidogrel Hydrogen Sulfate is used in the synthesis of Clopidogrel derivatives as platelet aggregation inhibitors. | | Biochem/physiol Actions | Inhibits ADP-induced platelet aggregation; anti-thrombotic drug. |
| | Clopidogrel hydrogen sulfate Preparation Products And Raw materials |
|
